Mammalian Polyclonal Immunoglobulin G (IgG) Antibody Global Market Report 2024

The mammalian polyclonal immunoglobulin G (IgG) antibody market size has grown strongly in recent years. It will grow from $1.22 billion in 2023 to $1.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to several factors, increasing focus on rare diseases, expanding applications in research, rising demand for therapeutic antibodies, evolving regulatory guidelines and quality standards, and the expansion of the biopharmaceutical sector.

The mammalian polyclonal immunoglobulin G (IgG) antibody market size is expected to see strong growth in the next few years. It will grow to $1.78 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to several factors, rising adoption in precision medicine, increasing research in immunotherapy, growing investments in biopharmaceutical research and development (R&D), emerging healthcare infrastructure, and a shift towards contract manufacturing. Major trends in the forecast period include technological advancements in antibody engineering, the emergence of next-generation sequencing (NGS) assays, advancements in biomarker discovery, advances in bioconjugation technologies, and advancements in therapeutic applications.

The growth in spending on animal health is expected to drive the expansion of the mammalian polyclonal immunoglobulin G (IgG) antibody markets in the future. Animal health encompasses comprehensive care and management practices focused on ensuring the well-being and longevity of various animals, including pets, livestock, and wildlife. The increased spending on animal health is attributed to several factors such as the rise in pet ownership, greater demand for animal products, advancements in veterinary care, stronger human-animal bonds, and stricter regulations. This heightened spending contributes to the demand for specialized mammalian polyclonal IgG antibodies, fostering innovation, collaboration with veterinarians, and market growth in the pet care sector. For example, in March 2023, the American Pet Products Association reported a significant 16.2% increase in spending on pet foods and treats, reaching $58.1 billion, marking it as the category with the largest growth. Hence, the upward trend in animal health spending is anticipated to drive the growth of the mammalian polyclonal IgG antibody market.

Key players in the mammalian polyclonal IgG antibody market are focusing on developing new therapeutics containing species-matched isotypes to enhance their therapeutic offerings and medication solutions. Species-matched isotypes are versions of antibodies engineered to match the species being studied or treated. For instance, Absolute Antibody, a UK-based provider of recombinant antibody products and services, introduced dog IgG2 (IgG-B) and dog IgG4 (IgG-D) isotypes in March 2022 for oncology research in dogs or as in vitro serological controls for canine immune responses. These species-matched isotypes minimize anti-species immune responses in animal models, improving antibody efficacy and cohort consistency. Canine IgG2 corresponds to human IgG1, while canine IgG4 corresponds to human IgG4.

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics innovator, acquired Abcam Limited for an undisclosed amount. This acquisition aimed to strengthen Danaher's capabilities and expand its market presence, benefiting both the company and its shareholders. Abcam Limited is a US-based producer, distributor, and seller of protein research tools, including rabbit polyclonal GFAP antibodies.

Major companies operating in the mammalian polyclonal immunoglobulin g (IgG) antibody market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories Inc., GeneTex, GenScript Biotech Corporation, Jackson ImmunoResearch Laboratories, Abcam Inc., R&D Systems, Sino Biological, Fortis Life Sciences, OriGene Technologies, Cell Signaling Technology Inc., Cedarlane Labs, Capralogics Inc, Proteintech Group, ProSci LLC, Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Novus Biologicals LLC, Creative Diagnostics, Fitzgerald Industries International Inc.

North America was the largest region in the mammalian polyclonal immunoglobulin G (IgG) antibody market in 2023. The regions covered in the mammalian polyclonal immunoglobulin g (IgG) antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mammalian polyclonal immunoglobulin g (IgG) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mammalian polyclonal IgG antibodies are a collection of immunoglobulin G antibodies produced by multiple B cells, providing diverse antigen recognition. They are widely used in research, diagnostics, and therapeutics for their ability to offer broad-spectrum immunity, crucial for detecting and neutralizing pathogens and antigens.

The main products derived from mammalian polyclonal IgG antibodies include cardiac markers, metabolic markers, renal markers, and others. Cardiac markers are molecules indicating heart health, commonly utilized in diagnostic tests to assess cardiac function and detect heart-related conditions such as myocardial infarction. These antibodies can be sourced from various mammals such as goats, rabbits, horses, mice, and others. They find applications in techniques such as enzyme-linked immunosorbent assay (ELISA), immunoturbidometry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting. End users of these antibodies include pharmaceutical and biotechnology companies, hospitals, diagnostic centers, academic and research centers.

The mammalian polyclonal immunoglobulin G (IgG) antibody market research report is one of a series of new reports that provides mammalian polyclonal immunoglobulin G (IgG) antibody market statistics, including the mammalian polyclonal immunoglobulin G (IgG) antibody industry global market size, regional shares, competitors with the mammalian polyclonal immunoglobulin G (IgG) antibody market share, detailed mammalian polyclonal immunoglobulin G (IgG) antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the mammalian polyclonal immunoglobulin G (IgG) antibody industry. These mammalian polyclonal immunoglobulin G (IgG) antibody market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mammalian polyclonal IgG antibody market consists of sales of infectious disease markers, autoimmune disease markers, tumor markers, and inflammatory markers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.